Stock Research Monitor: SHPG, SBOT, and SYN
LONDON, UK / ACCESSWIRE / June 20, 2018 / If you want a free Stock Review on SESN sign up now at www.wallstequities.com/registration. On Tuesday, benchmark US indices were in bearish colors as the NASDAQ Composite closed the trading session down 0.28%; the Dow Jones Industrial Average edged 1.15% lower; and the S&P 500 was down 0.40%. US markets made broad based losses with six out of nine sectors finishing the day in red. Pre-market today, WallStEquities.com reviews these four Biotechnology stocks: Sesen Bio Inc. (NASDAQ: SESN), Shire PLC (NASDAQ: SHPG), Stellar Biotechnologies Inc. (NASDAQ: SBOT), and Synthetic Biologics Inc. (NYSE American: SYN). All you have to do is sign up today for this free limited time offer by clicking the link below.
Cambridge, Massachusetts-based Sesen Bio Inc.'s stock finished Tuesday's session 4.98% lower at $2.10. A total volume of 1.07 million shares was traded. The Company's shares have advanced 85.84% over the previous three months and 51.08% in the last twelve months. The stock is trading above its 200-day moving average by 55.55%. Furthermore, shares of Sesen Bio, which develops next-generation antibody-drug conjugate therapies for patients with cancer, have a Relative Strength Index (RSI) of 45.59. Get the full research report on SESN for free by clicking below at:
Shares in Dublin, Ireland headquartered Shire PLC ended at $156.98, down 1.92% from the last trading session. The stock recorded a trading volume of 762,617 shares. The Company's shares have gained 21.48% over the previous three months. The stock is trading above its 200-day moving average by 5.16%. Moreover, shares of Shire, which researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide, have an RSI of 35.57. Gain free access to the research report on SHPG at:
Port Hueneme, California-based Stellar Biotechnologies Inc.'s stock ended yesterday's session 3.43% lower at $1.69 with a total trading volume of 145,969 shares. The stock is trading below its 50-day moving average by 51.79%. Additionally, shares of Stellar Biotechnologies, which engages in the aquaculture, research and development, manufacture, and commercialization of keyhole limpet hemocyanin protein in Europe, North America, and Asia, have an RSI of 30.09. Register for your free report coverage on SBOT at:
On Tuesday, shares in Rockville, Maryland headquartered Synthetic Biologics Inc. recorded a trading volume of 457,246 shares. The stock finished the day 3.68% lower at $0.21. The stock is trading below its 50-day moving average by 20.12%. Furthermore, shares of Synthetic Biologics, which develops therapeutics designed to preserve the microbiome to protect and restore the health of patients, have an RSI of 33.14. Get the free research report on SYN at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst. For further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: 21 32 044 483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Wall St. Equities